HK1104528A1 - Compounds and methods for treating dyslipidemia - Google Patents
Compounds and methods for treating dyslipidemiaInfo
- Publication number
- HK1104528A1 HK1104528A1 HK07109002.0A HK07109002A HK1104528A1 HK 1104528 A1 HK1104528 A1 HK 1104528A1 HK 07109002 A HK07109002 A HK 07109002A HK 1104528 A1 HK1104528 A1 HK 1104528A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- methods
- treating dyslipidemia
- dyslipidemia
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58270804P | 2004-06-24 | 2004-06-24 | |
US62724104P | 2004-11-12 | 2004-11-12 | |
US66486205P | 2005-03-24 | 2005-03-24 | |
PCT/US2005/022389 WO2006002342A1 (en) | 2004-06-24 | 2005-06-23 | Compounds and methods for treating dyslipidemia |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1104528A1 true HK1104528A1 (en) | 2008-01-18 |
Family
ID=35056992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07109002.0A HK1104528A1 (en) | 2004-06-24 | 2007-08-17 | Compounds and methods for treating dyslipidemia |
Country Status (27)
Country | Link |
---|---|
US (3) | US20080269284A1 (xx) |
EP (3) | EP1761521A1 (xx) |
JP (2) | JP2008504266A (xx) |
KR (1) | KR20070041452A (xx) |
CN (1) | CN1972932B (xx) |
AT (1) | ATE528304T1 (xx) |
AU (2) | AU2005267436A1 (xx) |
BR (2) | BRPI0512523A (xx) |
CA (2) | CA2570688A1 (xx) |
CR (1) | CR8831A (xx) |
CY (1) | CY1112124T1 (xx) |
DK (1) | DK1761522T3 (xx) |
EA (2) | EA200700119A1 (xx) |
EC (2) | ECSP067095A (xx) |
ES (1) | ES2372291T3 (xx) |
HK (1) | HK1104528A1 (xx) |
HR (1) | HRP20110761T1 (xx) |
IL (2) | IL180277A (xx) |
MA (2) | MA28729B1 (xx) |
MX (2) | MXPA06014716A (xx) |
NO (2) | NO20070468L (xx) |
NZ (1) | NZ550978A (xx) |
PL (1) | PL1761522T3 (xx) |
PT (1) | PT1761522E (xx) |
RS (1) | RS52064B (xx) |
SI (1) | SI1761522T1 (xx) |
WO (2) | WO2006012093A1 (xx) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4773969B2 (ja) * | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
DK1732933T3 (da) * | 2004-03-26 | 2008-10-27 | Lilly Co Eli | Forobindelser til behandling af dyslipidæmi |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
US20080269284A1 (en) | 2004-06-24 | 2008-10-30 | Eli Lilly And Company | Compounds and Methods for Treating Dyslipidemia |
WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2008143127A1 (ja) | 2007-05-17 | 2008-11-27 | Ajinomoto Co., Inc. | 脂質修飾酵素の活性測定法 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
US8785608B2 (en) | 2009-08-26 | 2014-07-22 | Sanofi | Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
TWI627167B (zh) * | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
PL2860175T3 (pl) * | 2012-06-11 | 2018-07-31 | Tacurion | Sposób wytwarzania związku 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepinowego i związku pośredniego do jego syntezy |
WO2014012401A1 (zh) * | 2012-07-16 | 2014-01-23 | 上海恒瑞医药有限公司 | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 |
AU2014381733B2 (en) * | 2014-02-05 | 2020-09-03 | Newamsterdam Pharma B.V. | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
CN103833637B (zh) * | 2014-03-31 | 2016-01-06 | 武汉武药制药有限公司 | 一种制备依塞曲匹(Evacetrapib)中间体的方法 |
LT3307734T (lt) | 2015-06-09 | 2020-05-11 | Abbvie Inc. | Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui |
WO2016198908A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2402506A1 (fr) * | 1977-09-09 | 1979-04-06 | Guelennec Emile Le | Cisaille pour la decoupe de ferrailles de grandes dimensions |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
RU2265010C2 (ru) * | 2001-04-30 | 2005-11-27 | Пфайзер Продактс Инк. | Промежуточные соединения для ингибиторов cetp и способы их получения |
SK2332004A3 (en) | 2002-08-30 | 2004-12-01 | Japan Tobacco Inc | Dibenzylamine compound and medicinal use thereof |
MXPA05003456A (es) | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
US20060100239A1 (en) | 2003-03-04 | 2006-05-11 | Izuru Nagasaki | Method for producing optically active amines |
US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
JP4773969B2 (ja) | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
DK1732933T3 (da) | 2004-03-26 | 2008-10-27 | Lilly Co Eli | Forobindelser til behandling af dyslipidæmi |
UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
US20080269284A1 (en) | 2004-06-24 | 2008-10-30 | Eli Lilly And Company | Compounds and Methods for Treating Dyslipidemia |
US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
-
2005
- 2005-06-22 US US11/570,540 patent/US20080269284A1/en not_active Abandoned
- 2005-06-22 CA CA002570688A patent/CA2570688A1/en not_active Abandoned
- 2005-06-22 BR BRPI0512523-5A patent/BRPI0512523A/pt not_active Application Discontinuation
- 2005-06-22 KR KR1020067027038A patent/KR20070041452A/ko not_active Application Discontinuation
- 2005-06-22 WO PCT/US2005/021789 patent/WO2006012093A1/en active Application Filing
- 2005-06-22 JP JP2007518182A patent/JP2008504266A/ja active Pending
- 2005-06-22 AU AU2005267436A patent/AU2005267436A1/en not_active Abandoned
- 2005-06-22 EA EA200700119A patent/EA200700119A1/ru unknown
- 2005-06-22 EP EP05768995A patent/EP1761521A1/en not_active Withdrawn
- 2005-06-22 MX MXPA06014716A patent/MXPA06014716A/es not_active Application Discontinuation
- 2005-06-23 RS RS20110559A patent/RS52064B/en unknown
- 2005-06-23 AU AU2005258241A patent/AU2005258241B2/en not_active Ceased
- 2005-06-23 AT AT05763328T patent/ATE528304T1/de active
- 2005-06-23 SI SI200531438T patent/SI1761522T1/sl unknown
- 2005-06-23 PL PL05763328T patent/PL1761522T3/pl unknown
- 2005-06-23 NZ NZ550978A patent/NZ550978A/en not_active IP Right Cessation
- 2005-06-23 US US11/570,542 patent/US7786108B2/en not_active Expired - Fee Related
- 2005-06-23 CN CN2005800206855A patent/CN1972932B/zh not_active Expired - Fee Related
- 2005-06-23 JP JP2007518296A patent/JP4836945B2/ja not_active Expired - Fee Related
- 2005-06-23 BR BRPI0512516-2A patent/BRPI0512516A/pt active Search and Examination
- 2005-06-23 EP EP05763328A patent/EP1761522B1/en active Active
- 2005-06-23 PT PT05763328T patent/PT1761522E/pt unknown
- 2005-06-23 DK DK05763328.1T patent/DK1761522T3/da active
- 2005-06-23 EP EP11184746A patent/EP2479175A1/en not_active Withdrawn
- 2005-06-23 MX MXPA06014706A patent/MXPA06014706A/es active IP Right Grant
- 2005-06-23 ES ES05763328T patent/ES2372291T3/es active Active
- 2005-06-23 CA CA2570673A patent/CA2570673C/en not_active Expired - Fee Related
- 2005-06-23 WO PCT/US2005/022389 patent/WO2006002342A1/en active Application Filing
- 2005-06-23 EA EA200700120A patent/EA012585B1/ru not_active IP Right Cessation
-
2006
- 2006-12-19 EC EC2006007095A patent/ECSP067095A/es unknown
- 2006-12-19 EC EC2006007098A patent/ECSP067098A/es unknown
- 2006-12-22 CR CR8831A patent/CR8831A/es unknown
- 2006-12-24 IL IL180277A patent/IL180277A/en not_active IP Right Cessation
- 2006-12-24 IL IL180276A patent/IL180276A0/en unknown
- 2006-12-29 MA MA29595A patent/MA28729B1/fr unknown
- 2006-12-29 MA MA29596A patent/MA28730B1/fr unknown
-
2007
- 2007-01-24 NO NO20070468A patent/NO20070468L/no not_active Application Discontinuation
- 2007-01-24 NO NO20070470A patent/NO20070470L/no not_active Application Discontinuation
- 2007-08-17 HK HK07109002.0A patent/HK1104528A1/xx not_active IP Right Cessation
-
2010
- 2010-04-20 US US12/763,344 patent/US20100204207A1/en not_active Abandoned
-
2011
- 2011-10-19 HR HR20110761T patent/HRP20110761T1/hr unknown
- 2011-11-25 CY CY20111101160T patent/CY1112124T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL180276A0 (en) | Compounds and methods for treating dyslipidemia | |
IL177962A0 (en) | Compounds and methods for treating dyslipidemia | |
WO2006028958A3 (en) | Pyridyl inhibitors of hedgehog signalling | |
HK1109140A1 (en) | Potentiators of glutamate receptors | |
WO2005111002A3 (de) | Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen | |
MY148538A (en) | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | |
TW200716529A (en) | New compounds II | |
IL173819A0 (en) | Compounds and methods for treating dyslipidemia | |
TW200740781A (en) | Novel compounds | |
TW200744567A (en) | Phenylethylamine analogs and their use for treating glaucoma | |
TW200722418A (en) | Novel compounds | |
TW200716530A (en) | New compounds I |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160623 |